UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Sex differences in the psychopharmacological treatment of depression

Dialogues in clinical neuroscience, 2016-12, Vol.18 (4), p.447-457

2016

Volltextzugriff (PDF)

Phase 1 Clinical Trials of Small Molecules: Evolution and State of the Art

Reviews on recent clinical trials, 2021-01, Vol.16 (3), p.232-241

2021

Volltextzugriff (PDF)

A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition

Journal of clinical psychopharmacology, 2004-02, Vol.24 (1), p.62-69

2004

Volltextzugriff (PDF)

Galantamine hydrobromide: an agent for Alzheimer's disease

American journal of health-system pharmacy, 2003-03, Vol.60 (5), p.446-452

2003

Volltextzugriff (PDF)

Lurasidone in post-menopausal females with major depressive disorder with mixed features: Post-hoc analysis of a placebo-controlled trial

Progress in neuro-psychopharmacology & biological psychiatry, 2017-08, Vol.78, p.12-17

2017

Volltextzugriff (PDF)

Cholinesterase inhibitors: a therapeutic strategy for Alzheimer disease

The Annals of pharmacotherapy, 1999-04, Vol.33 (4), p.441-450

1999

Volltextzugriff (PDF)

Bivariate evaluation of thromboembolism and bleeding in clinical trials of anticoagulants in patients with atrial fibrillation

Thrombosis and haemostasis, 2016-09, Vol.116 (3), p.544-553

2016

Volltextzugriff (PDF)

Pleocytosis in cerebrospinal fluid following multiple lumbar punctures in healthy volunteers

Journal of the neurological sciences, 2016-01, Vol.360, p.131-132

2016

Volltextzugriff (PDF)

Critical Pathways to Success in CNS Drug Development

2, 2010

Volltextzugriff (PDF)

Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial

JAMA : the journal of the American Medical Association, 1998-11, Vol.280 (20), p.1752

1998

Volltextzugriff (PDF)

The effect of naltrexone on sleep parameters in healthy male volunteers

Journal of clinical psychopharmacology, 2014-02, Vol.34 (1), p.167-168

2014

Volltextzugriff (PDF)

Exploratory Biomarker Study of the Triple Reuptake Inhibitor SEP‐432 Compared to the Dual Reuptake Inhibitor Duloxetine in Healthy Normal Subjects

CNS neuroscience & therapeutics, 2016-05, Vol.22 (5), p.404-412

2016

Volltextzugriff (PDF)

Improving academic leadership and oversight in large industry-sponsored clinical trials: the ARO-CRO model

Blood, 2011-02, Vol.117 (7), p.2089-2092

2011

Volltextzugriff (PDF)

Generalised anxiety disorder: Treatment options

Drugs (New York, N.Y.), 2002, Vol.62 (11), p.1635-1648

2002

Volltextzugriff (PDF)

Review of the acetylcholinesterase inhibitor galanthamine

Expert opinion on investigational drugs, 2000-10, Vol.9 (10), p.2393-2402

2000

Volltextzugriff (PDF)

Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: A comparative review

Clinical pharmacokinetics, 2001, Vol.40 (3), p.189-205

2001

Volltextzugriff (PDF)

The impact of gender on antidepressants

Current topics in behavioral neurosciences, 2011, Vol.8, p.231

2011

Volltextzugriff (PDF)

Review of the next generation of Alzheimer's disease therapeutics: challenges for drug development

Progress in neuro-psychopharmacology & biological psychiatry, 2001, Vol.25 (1), p.27-57

2001

Volltextzugriff (PDF)

Gender differences in depression and antidepressant pharmacokinetics and adverse events

The Annals of pharmacotherapy, 2000-01, Vol.34 (1), p.80-88

2000

Volltextzugriff (PDF)

Placebo-controlled evaluation of three doses of a controlled-onset, extended-release formulation of verapamil in the treatment of stable angina pectoris

The American journal of cardiology, 1995-06, Vol.75 (16), p.1102-1106

1995

Volltextzugriff (PDF)

Combined Enalapril and Felodipine Extended Release (ER) for Systemic Hypertension

The American journal of cardiology, 1997-02, Vol.79 (4), p.431-435

1997

Volltextzugriff (PDF)

Cholinergic Rebound and Rapid Onset Psychosis Following Abrupt Clozapine Withdrawal

Schizophrenia bulletin, 1996, Vol.22 (4), p.591-595

1996

Volltextzugriff (PDF)

P1‐335: AN EVALUATION OF INDEPENDENT SUBJECT ELIGIBILITY REVIEWS TO ENSURE ENROLLMENT OF HIGH QUALITY APPROPRIATE SUBJECTS IN MILD ALZHEIMER'S DISEASE (AD) TRIALS

Alzheimer's & dementia, 2018-07, Vol.14 (7S_Part_7), p.P421-P421

2018

Volltextzugriff (PDF)

AN EVALUATION OF INDEPENDENT SUBJECT ELIGIBILITY REVIEWS TO ENSURE ENROLLMENT OF HIGH QUALITY APPROPRIATE SUBJECTS IN MILD ALZHEIMER’S DISEASE (AD) TRIALS

Alzheimer's & dementia, 2018-07, Vol.14 (7), p.P421-P421

2018

Volltextzugriff (PDF)

RBC cholinesterase inhibition : A useful surrogate marker for cholinesterase inhibitor activity in Alzheimer disease therapy?

Alzheimer disease and associated disorders, 2000-10, Vol.14 (4), p.216-227

2000

Volltextzugriff (PDF)

1 – 25 von 236

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(197)
Mit Volltextzugriff
(155)

Publikationsform

Sprache

Englisch
(236)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(163)
Humans
(161)
Life Sciences & Biomedicine
(157)
Male
(110)
Biological And Medical Sciences
(95)
Female
(93)
Medical Sciences
(90)
Middle Aged
(88)
Pharmacology & Pharmacy
(72)
Adult
(64)
Aged
(64)
Pharmacology. Drug Treatments
(62)
Double-Blind Method
(46)
Neurosciences & Neurology
(43)
Neuropharmacology
(42)
Psychiatry
(39)
Alzheimer Disease - Drug Therapy
(36)
Psychology. Psychoanalysis. Psychiatry
(36)
Clinical Neurology
(33)
Psychopharmacology
(28)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Sex differences in the psychopharmacological treatment of depression

Phase 1 Clinical Trials of Small Molecules: Evolution and State of the Art

A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition

Galantamine hydrobromide: an agent for Alzheimer's disease

Lurasidone in post-menopausal females with major depressive disorder with mixed features: Post-hoc analysis of a placebo-controlled trial

Cholinesterase inhibitors: a therapeutic strategy for Alzheimer disease

Bivariate evaluation of thromboembolism and bleeding in clinical trials of anticoagulants in patients with atrial fibrillation

Pleocytosis in cerebrospinal fluid following multiple lumbar punctures in healthy volunteers

Critical Pathways to Success in CNS Drug Development

Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial

The effect of naltrexone on sleep parameters in healthy male volunteers

Exploratory Biomarker Study of the Triple Reuptake Inhibitor SEP‐432 Compared to the Dual Reuptake Inhibitor Duloxetine in Healthy Normal Subjects

Improving academic leadership and oversight in large industry-sponsored clinical trials: the ARO-CRO model

Generalised anxiety disorder: Treatment options

Review of the acetylcholinesterase inhibitor galanthamine

Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: A comparative review

The impact of gender on antidepressants

Review of the next generation of Alzheimer's disease therapeutics: challenges for drug development

Gender differences in depression and antidepressant pharmacokinetics and adverse events

Placebo-controlled evaluation of three doses of a controlled-onset, extended-release formulation of verapamil in the treatment of stable angina pectoris

Combined Enalapril and Felodipine Extended Release (ER) for Systemic Hypertension

Cholinergic Rebound and Rapid Onset Psychosis Following Abrupt Clozapine Withdrawal

P1‐335: AN EVALUATION OF INDEPENDENT SUBJECT ELIGIBILITY REVIEWS TO ENSURE ENROLLMENT OF HIGH QUALITY APPROPRIATE SUBJECTS IN MILD ALZHEIMER'S DISEASE (AD) TRIALS

AN EVALUATION OF INDEPENDENT SUBJECT ELIGIBILITY REVIEWS TO ENSURE ENROLLMENT OF HIGH QUALITY APPROPRIATE SUBJECTS IN MILD ALZHEIMER’S DISEASE (AD) TRIALS

RBC cholinesterase inhibition : A useful surrogate marker for cholinesterase inhibitor activity in Alzheimer disease therapy?

Suchergebnisse filtern